A Study of Patient Preference Between Cabazitaxel and Docetaxel in First-line Chemotherapy for Metastatic Castrate-resistant Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 10 Aug 2017
At a glance
- Drugs Cabazitaxel (Primary) ; Docetaxel (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms CABA-DOC
- 07 Aug 2017 Planned End Date changed from 1 May 2017 to 1 Apr 2018.
- 07 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 05 Feb 2016 Planned End Date changed from 1 Feb 2016 to 1 May 2017 as per ClinicalTrials.gov record.